Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10962782 | Vaccine | 2016 | 7 Pages |
Abstract
Based on our improved novel Salmonella vaccine delivery platform, we optimized the recombinant attenuated Salmonella typhimurium vaccine (RASV) Ï12094 to deliver multiple Yersinia pestis antigens. These included LcrV196 (amino acids, 131-326), Psn encoded on pYA5383 and F1 encoded in the chromosome, their synthesis did not cause adverse effects on bacterial growth. Oral immunization with Ï12094(pYA5383) simultaneously stimulated high antibody titers to LcrV, Psn and F1 in mice and presented complete protection against both subcutaneous (s.c.) and intranasal (i.n.) challenges with high lethal doses of Y. pestis CO92. Moreover, no deaths or other disease symptoms were observed in SCID mice orally immunized with Ï12094(pYA5383) over a 60-day period. Therefore, the trivalent S. typhimurium-based live vaccine shows promise for a next-generation plague vaccine.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Shilpa Sanapala, Hannah Rahav, Hetal Patel, Wei Sun, Roy 3rd,